Cancer Biotherapy and Radiopharmaceuticals (image) Mary Ann Liebert, Inc./Genetic Engineering News Caption Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year in print and online, is under the editorial leadership of editors Donald J. Buchsbaum, Ph.D., and Robert K. Oldham, M.D., Lower Keys Cancer Center, Key West, Fla. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. Tables of content and a sample issue are available on the Cancer Biotherapy and Radiopharmaceuticals website. Credit © Mary Ann Liebert Inc publishers Usage Restrictions None Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.